---
title: "CytoMed Therapeutics Limited (GDTC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GDTC.US.md"
symbol: "GDTC.US"
name: "CytoMed Therapeutics Limited"
industry: "Biotechnology"
datetime: "2026-05-20T10:45:42.010Z"
locales:
  - [en](https://longbridge.com/en/quote/GDTC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GDTC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GDTC.US.md)
---

# CytoMed Therapeutics Limited (GDTC.US)

## Company Overview

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [w2.cytomed.sg](https://w2.cytomed.sg) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 166 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 76.37% |  |
| Net Profit YoY | -63.11% |  |
| P/B Ratio | 2.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14317730.35 |  |
| Revenue | 664065.87 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -51.33% | E |
| Profit Margin | -462.39% | E |
| Gross Margin | 89.57% | A |
| Revenue YoY | 76.37% | A |
| Net Profit YoY | -63.11% | D |
| Total Assets YoY | -15.99% | E |
| Net Assets YoY | -19.73% | E |
| Cash Flow Margin | 92.89% | C |
| OCF YoY | 76.37% | A |
| Turnover | 0.10 | E |
| Gearing Ratio | 14.17% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CytoMed Therapeutics Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "76.37%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.11%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14317730.35",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "664065.87",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-51.33%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-462.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "89.57%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "76.37%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.11%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.99%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-19.73%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "92.89%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "76.37%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.17%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.66 | 371/386 | - | - | - |
| PB | 2.81 | 248/386 | 3.94 | 3.27 | 2.22 |
| PS (TTM) | 21.56 | 198/386 | 61.45 | 39.46 | 21.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2024-10-10T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.21 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GDTC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GDTC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GDTC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GDTC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**